CST-3056

CST-3056
Clinical data
Other namesCST3056; CuraAX
Routes of
administration		Oral[1][2]
Drug classα1-Adrenergic receptor agonist

CST-3056, also known as CuraAX, is an α1A-adrenergic receptor agonist which is under development for the treatment of neurogenic orthostatic hypotension (nOH) (e.g. due to pure autonomic failure (PAF)), Parkinson's disease, and Alzheimer's disease.[1][3][2][4] It is taken orally.[1][2]

The drug is a centrally penetrant selective partial agonist of the α1A-adrenergic receptor.[2][4] nOH frequently occurs in neurodegenerative diseases like Parkinson's disease and Alzheimer's disease and CST-3056 is in part aimed to treat these cases, including to both stabilize blood pressure and improve cerebral perfusion (brain blood flow).[2][4]

CST-3056 is under development by CuraSen Therapeutics.[1][3][4] As of November 2025, it is in phase 2 clinical trials for treatment of orthostatic hypotension and the preclinical research stage of development for Alzheimer's disease.[1][3][4] The chemical structure of CST-3056 does not yet appear to have been disclosed.[1]

See also

References

  1. ^ a b c d e f "CuraAX". AdisInsight. Springer Nature Switzerland AG. 19 November 2025. Retrieved 13 March 2026.
  2. ^ a b c d e "CST-3056". ALZFORUM. 30 December 2025. Retrieved 13 March 2026.
  3. ^ a b c "Delving into the Latest Updates on CuraAX". Synapse. PatSnap. 18 September 2025. Retrieved 13 March 2026.
  4. ^ a b c d e Debbarma S (24 October 2025). "CuraSen begins Phase IIa trial for neurogenic orthostatic hypotension". Clinical Trials Arena. Retrieved 13 March 2026.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.